|
May 11
|
New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
|
|
May 10
|
Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
|
|
May 7
|
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
|
|
May 7
|
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
EyePoint Pharmaceuticals: Q1 Earnings Snapshot
|
|
May 7
|
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
|
|
Feb 26
|
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
|
|
Feb 25
|
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
|
|
Feb 11
|
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
|
|
Sep 4
|
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
|
|
Aug 27
|
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
|
|
Jul 15
|
Milestone Pharmaceuticals Refreshes Board of Directors
|
|
Jun 26
|
EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
|
|
May 17
|
Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
|
|
May 10
|
EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges
|
|
May 8
|
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
|
|
May 6
|
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
|
|
May 6
|
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
|
|
Apr 2
|
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
|
|
Mar 9
|
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%
|